Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Accelerator Applications SA

Division of Novartis AG
www.adacap.com

Latest From Advanced Accelerator Applications SA

Priority Review Vouchers Post Lower Average Approval Times Than Priority NMEs

US FDA’s priority review voucher program delivers for most sponsors, a Pink Sheet analysis finds; PRVs reliably produce faster approval than priority-reviewed new drugs overall.

Review Pathway Regulation

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Hudson To Succeed Brandicourt As Sanofi CEO

All change at the top for Sanofi which has poached Novartis pharma chief Paul Hudson to succeed Olivier Brandicourt as CEO.

Leadership Strategy

CHMP Highlights: No For Xyndari, Edaravone MAA Pulled And Good News For Univar’s Cufence

This month’s meeting of the European Medicines Agency’s CHMP appears to have been eventful. One marketing authorization application was rejected, one was pulled, and an earlier negative opinion was upheld. Four MAAs were recommended for approval, including a new treatment from Univar for Wilson’s disease.

Europe Regulation
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Stefano Buono, CEO
    Heinz Mausli, CFO
    Claude Hariton, Head, R&D
    Gerard Ber, COO
  • Contact Info
  • Advanced Accelerator Applications SA
    Phone: 4 50 99 30 70
    20 Rue Diesel
    Saint Genis Pouilly, 01630
    France
UsernamePublicRestriction

Register